Medtronic Stock News

Medtronic (NYSE:MDT) issued an update on its FY 2022 earnings guidance on Tuesday morning. The company provided EPS guidance of $5.650-$5.750 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.710. The company issued revenue guidance of -.Medtronic also updated its FY22 guidance to $5.65-5.75 EPS. NYSE:MDT traded down $3.41 during mid-day []

Edge Wealth Management LLC lowered its position in shares of Medtronic plc (NYSE:MDT) by 5.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 39,081 shares of the medical technology companys stock after selling 2,315 shares during the quarter. Medtronic makes up approximately []

Stocks that traded heavily or had substantial price changes Tuesday: Best Buy, Medtronic fall; Dollar Tree, Dycom rise

Aries Wealth Management grew its position in Medtronic plc (NYSE:MDT) by 3.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,950 shares of the medical technology companys stock after acquiring an additional 114 shares during the quarter. Aries Wealth Managements holdings in Medtronic []

A nursing shortage in the U.S. was a factor hurting medical-device giant Medtronic, noted CEO Geoff Martha. He says the company is doubling down on its investments.

The global Cutter Stapler market was valued at 1250.55 Million USD in 2020 and will grow with a CAGR of 4.82% from 2021 to 2027. One of the key growth boosters for the market has been the growing demand for

Early Tuesday, Medtronic reported earnings of $1.32 a share on $7.85 billion in sales. In response, MDT stock sank.

Medtronic plc (MDT) CEO Geoffrey Martha on Q2 2022 Results - Earnings Call Transcript

Here are seven top tech stocks worth considering for investors taking a truly long-term view of the growth sector relative to the market. The post 7 Top Tech Stocks to Buy Despite Recent Tapering Conc

Medtronic (MDT) cuts revenue growth guidance for the full year on the projection of a severe pandemic impact to continue through the rest of the year.

Shares of Medtronic PLC dropped 1.2% toward an eight-month low in premarket trading Tuesday, after the medical technology company beat fiscal second-quarter profit expectations but missed on revenue, citing the negative impact of the COVID-19 pandemic resurgence and healthcare staffing challenges on medical procedure volumes. Net income for the quarter to Oct. 29 nearly tripled to $1.31 billion, or 97 cents a share, from $489 million, or 36 cents a share, in the year-ago period. Revenue rose 2.6% to $7.85 billion but was below the FactSet consensus of $7.97 billion, while cost of sales fell 7.7%. Cardiovascular revenue rose 3.7% to $2.83 billion, medical surgical revenue increased 0.6% to $2.30 billion, neuroscience revenue fell 0.4% to $1.07 billion and diabetes revenue grew 1.9% to $585 million. For fiscal 2022, the company affirmed its adjusted EPS guidance range of $5.65 to $5.75, but cut its revenue growth outlook to 7% to 8% from 9%. The stock has shed 9.0% over the past three months through Monday, while the SPDR Health Care Select Sector ETF has slipped 2.8% and the S&P 500 has gained 4.5%.

Medtronic Earnings Beat, Revenue Misses In Q2